AC Immune Operating Income 2016-2021 | ACIU

AC Immune operating income from 2016 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
AC Immune Annual Operating Income
(Millions of US $)
2020 $-65
2019 $45
2018 $-51
2017 $-23
2016 $-11
2015 $19
AC Immune Quarterly Operating Income
(Millions of US $)
2021-09-30 $-22
2021-06-30 $-21
2021-03-31 $-19
2020-12-31 $-21
2020-09-30 $-20
2020-06-30 $-16
2020-03-31 $-8
2019-12-31 $-19
2019-09-30 $18
2019-06-30 $-15
2019-03-31 $60
2018-12-31 $-15
2018-09-30 $-12
2018-06-30 $-12
2018-03-31 $-12
2017-12-31 $3
2017-09-30 $-10
2017-06-30 $-8
2017-03-31 $-8
2016-09-30 $-8
2016-06-30
2016-03-31 $-6
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.376B $0.016B
AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09